drugset / Trial / NCT02667470

Reproducibility Study of OABSS and Its Response to Treatment

NCT02667470

Phase 4 Completed 50 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate change of Overactive Bladder (OAB) Symptom Score (OABSS) scores between before and after Solifenacin treatment to OAB patients and to evaluate correlation between change of OABSS scores and other measures for OAB symptoms.

Timeline

Start
2009-09
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule Oral

Indications